share_log

Despite Delivering Investors Losses of 65% Over the Past 3 Years, STAAR Surgical (NASDAQ:STAA) Has Been Growing Its Earnings

Despite Delivering Investors Losses of 65% Over the Past 3 Years, STAAR Surgical (NASDAQ:STAA) Has Been Growing Its Earnings

尽管在过去3年中给投资者带来了65%的损失,但STAAR Surgical(纳斯达克股票代码:STAA)的收益一直在增长
Simply Wall St ·  04/25 15:56

It is doubtless a positive to see that the STAAR Surgical Company (NASDAQ:STAA) share price has gained some 61% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 65% in the last three years. So the improvement may be a real relief to some. While many would remain nervous, there could be further gains if the business can put its best foot forward.

毫无疑问,STAAR外科公司(纳斯达克股票代码:STAA)的股价在过去三个月中上涨了约61%,这是一个积极因素。但是,对于三年来的惊人回报来说,这只是微不足道的回报。事实上,股价在过去三年中悲惨地下跌了65%。因此,这种改善可能使某些人松了一口气。尽管许多人仍会感到紧张,但如果企业能够尽力而为,可能会有进一步的收益。

The recent uptick of 3.2% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上涨3.2%可能是即将发生的事情的积极信号,因此让我们来看一下历史基本面。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

不可否认,市场有时是有效的,但价格并不总是能反映潜在的业务表现。评估公司情绪变化的一种有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。

Although the share price is down over three years, STAAR Surgical actually managed to grow EPS by 50% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.

尽管股价在三年内下跌,但在此期间,STAAR Surgical实际上设法将每股收益每年增长50%。鉴于股价的反应,人们可能会怀疑每股收益并不能很好地指导该期间的业务表现(可能是由于一次性的亏损或收益)。否则,该公司过去曾被过度炒作,因此其增长令人失望。

It's worth taking a look at other metrics, because the EPS growth doesn't seem to match with the falling share price.

值得一看其他指标,因为每股收益的增长似乎与股价的下跌不符。

Revenue is actually up 21% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating STAAR Surgical further; while we may be missing something on this analysis, there might also be an opportunity.

在过去的三年中,收入实际上增长了21%,因此股价下跌似乎也不取决于收入。可能值得进一步研究STAAR Surgical;虽然我们在分析中可能遗漏了一些东西,但也可能有机会。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
NasdaqGM:STAA Earnings and Revenue Growth April 25th 2024
纳斯达克通用汽车公司:STAA 收益和收入增长 2024 年 4 月 25 日

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on STAAR Surgical

我们认为,内部人士在去年进行了大量收购,这是积极的。话虽如此,大多数人认为收益和收入增长趋势是更有意义的业务指南。这份显示分析师预测的免费报告应该可以帮助您对STAAR Surgical形成看法

A Different Perspective

不同的视角

STAAR Surgical shareholders are down 29% for the year, but the market itself is up 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for STAAR Surgical you should know about.

STAAR Surgical的股东今年下跌了29%,但市场本身上涨了27%。但是,请记住,即使是最好的股票有时也会在十二个月内表现不如市场。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚8%。最近的抛售可能是一个机会,因此可能值得查看基本面数据以寻找长期增长趋势的迹象。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,考虑风险。每家公司都有它们,我们发现了一个你应该知道的STAAR Surgical警告信号。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

还有很多其他公司有内部人士购买股票。你可能不想错过这份业内人士正在收购的成长型公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发